Biophysics pioneer Depixus launches Research Program enabling free access to the power of single molecule interactomics

French biophysics pioneer Depixus has launched its inaugural Research Program, offering free access to the company’s unique single molecule interactomics technology.

Depixus’ scalable magnetic force spectroscopy (MFS) platform is the first technology that allows researchers to simultaneously explore dynamic interactions between thousands of individual molecules in near real-time.

The platform is able to analyze interactions between various combinations of RNA, DNA, proteins, and small molecules, providing unprecedented insights into mechanisms of action, binding kinetics and more. It is particularly useful for exploring challenging drug targets such as RNA and protein-protein interactions.

Researchers at any established scientific institute are welcome to apply for the Research Program by submitting a simple online proposal outlining the biomolecular interactions they wish to explore. One winning applicant will be selected to have their proposed experiments run for free by Depixus’ expert team in Paris.

Pascale Beurdeley, Senior Vice President of Product Development at Depixus, said, “We are delighted to open up our Research Program to the scientific community and excited to hear their ideas. We hope that our technology will inspire researchers to ask questions they have not previously been able to answer with existing biophysical techniques and enable them to see biology as it really happens.”

Applications for the Depixus Research Program close on August 31st with the winner announced in September and sample intake commencing in October.

Learn more about the power of scalable MFS technology and its applications at Depixus.com. For full details and to apply for the Depixus Research Program, visit https://bit.ly/DepixusResearchProgram

About Depixus
Depixus is a life science technology company pioneering ground-breaking MAGNA™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. MAGNA enables researchers to decode disease mechanisms and unlock faster routes to more effective therapies.

Depixus is continuing to expand its partnerships with global leaders in the development of novel RNA-targeted small molecule therapeutics. For more information visit www.depixus.com, engage with us on LinkedIn, or email info@depixus.com